PAO Group, Inc. PAOG, a holding company focused on alternative patient treatments, confirmed Friday it will launch a CBD Nutraceuticals line of products.
The company will create and sell new CBD nutraceuticals together with Alkame Holdings, Inc. ALKM, which will take on the role of co-packer, and North American Cannabis Holdings, Inc. USMJ whose team will help with distribution services.
PAOG is currently working on a CBD pharmaceutical product called RespRx as therapy for chronic obstructive pulmonary disorder. The product is derived from a patented cannabis extraction method.
CBD Nutraceuticals is expected to generate revenue this year, as the first three products will be launched during the fourth quarter of 2021:
- The first CBD nutraceutical, still in development, will be called CBD Relax-Rx and be used to treat anxiety and depression - a market projected to be worth around $18 billion by 2025.
- The second CBD product from the line, also in progress, is being developed from the company’s current research on the treatment of COPD, although separate from the pharmaceutical market.
- The third CBD nutraceutical being developed in collaboration with EVERx CBD Sports Water, which is owned by Puration, Inc. PURA, will target the sports nutrition market.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.